Aprea Therapeutics (APRE) Misses Q3 EPS by 47c

Aprea Therapeutics (NASDAQ: APRE) reported Q3 EPS of ($0.47). Revenue for the quarter came in at $1.84 million.

For earnings history and earnings-related data on Aprea Therapeutics (APRE) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens
• Amgen (AMGN) PT Raised to $410 at Jefferies